News & Views | Telix Pharmaceuticals Limited

Telix Commences Phase III Clinical Trial of Prostate Cancer Therapy

Telix has been granted HREC approval and received CTN clearance by the TGA to commence a Phase III study of the Company’s prostate cancer therapy candidate TLX591, in patients with advanced prostate cancer.

Telix Announces Executive Leadership Appointments and Establishment of Asia Pacific Operating Region

Telix announces several key executive leadership appointments, including the establishment of an Asia-Pacific (APAC) operating region, further continuing the Company’s rapid commercial growth.

Telix Pharmaceuticals Appoints Richard Valeix as EMEA President

Telix announces Richard Valeix has joined the Telix executive leadership team in the role of President, Europe, Middle East and Africa (EMEA).

Telix Pharmaceuticals and Global Medical Solutions Complete Strategic Manufacturing Agreement

Telix announces it has completed a strategic manufacturing agreement with Global Medical Solutions to manufacture and supply finished unit doses of MTR products for clinical development programs.

Japanese Renal Cancer Imaging Trial Meets Study Objectives

Telix announces the Company’s ZIRDAC-JP study of its renal cancer imaging product demonstrates safety and tolerability in Japanese patients.

Launch of the International NOBLE Registry of Telix’s SPECT-Based Prostate Cancer Imaging Agent

Telix announces the launch of the international NOBLE Registry of Telix’s ‘rest of world’ prostate cancer imaging agent and the dosing of the first patient

Australian TGA Accepts Telix’s Prostate Cancer Imaging Product Submission and Commences Priority Evaluation Process

Telix announces the Australian Therapeutic Goods Administration has accepted its prostate cancer imaging product submission and commenced the priority evaluation process

Telix Pharmaceuticals Limited – Notice of Annual General Meeting 2021

Telix Pharmaceuticals provides notice of The Annual General Meeting of Shareholders on Wednesday 12 May 2021

Telix Pharmaceuticals and Grand River Aseptic Manufacturing Complete Agreement for Commercial Manufacturing of Illuccix®

Telix announces it has completed an agreement with Grand River Aseptic Manufacturing to perform GMP manufacturing of Telix’s prostate cancer imaging product.

Telix Appoints Darren Patti, Chief Operating Officer, Telix Pharmaceuticals (US) Inc.

Telix is delighted to announce the appointment of Darren Patti as Chief Operating Officer, Telix Pharmaceuticals US (Inc). Darren brings with him over 15 years’ experience in radiopharmacy network management and operations, including new radiopharmaceuticals implementation and compliance.